Using MRD Status to Deescalate Multiple Myeloma Therapy Joseph Mikhael, MD, leads a discussion on the findings of the MRD2STOP study Jun 20, 2024 video
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL High-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line Jun 19, 2024
Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopenia "Rapid and sustained" efficacy in 95% of pretreated patients in small trial Jun 19, 2024
Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL Undetectable MRD rates of 90% or higher, PFS of 7 years or more Jun 17, 2024
New Standard of Care in High-Risk Acute Promyelocytic Leukemia? All-trans retinoic acid plus arsenic trioxide and idarubicin improved EFS over standard Jun 17, 2024
Atezolizumab Consolidation Impresses in High-Risk DLBCL Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation? Jun 14, 2024
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma Joseph Mikhael, MD, leads a roundtable discussion on two positive phase III trials from ASCO Jun 14, 2024 video
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break? News, features, and commentary about cancer-related issues Jun 13, 2024
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy Co-mutations, viral link, potential common susceptibility emerge from two studies Jun 12, 2024
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study Second-gen ALK inhibitor induces high response rate, associated with impressive survival Jun 12, 2024
Telomerase Inhibitor Approved for MDS-Related Anemia Imetelstat indicated for lower-risk myelodysplastic syndromes with transfusion-dependent anemia Jun 07, 2024
Near-Perfect Control of Slow-Growing Lymphoma With Low-Dose Radiotherapy All but four of 24 patients had complete responses to 4 Gy, local control rate of 96% at 3 years Jun 06, 2024
'Unusual' Cancers After Pandemic; A Win in TNBC; Shortage Pauses Clinical Trial News, features, and commentary about cancer-related issues Jun 06, 2024
Star Singer's Illness; AI Imitating the Dead; Internet-Addicted Brains Health news and commentary gathered by Ƶ staff Jun 05, 2024
Triplet Notches Survival Win in Heavily Pretreated DLBCL Benefit with BV plus lenalidomide-rituximab seen in those who relapsed after CAR-T or transplant Jun 02, 2024
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma Second belantamab mafodotin-containing triplet to show potency in this setting Jun 02, 2024
Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial Better efficacy with brentuximab vedotin versus standard chemo, substantially less toxicity Jun 01, 2024
Fewer Suicides in Cancer Patients; Circadian Rhythm Boost; HIV Vaccine for Cancer? News, features, and commentary about cancer-related issues May 31, 2024
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML The benefit-risk profile could change the treatment paradigm in CML, expert says May 31, 2024
Tattoos May Be a Risk Factor for Lymphoma Swedish study suggests a 21% higher risk for lymphoma in those with tattoos May 28, 2024
Doubt Cast on MGUS-Autoimmune Disease Link Population-based study fails to confirm earlier findings May 20, 2024
What to Know About the U.K.'s Tainted Blood Scandal Tens of thousands contracted HIV or hepatitis from transfusions during the 1970s and 1980s May 20, 2024
Mortality in U.S. Youth; Gene Therapy for Sickle Cell Disease Also in TTHealthWatch: updated breast cancer screening guidelines May 11, 2024 podcast
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise News, features, and commentary about cancer-related issues May 10, 2024
Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show Study finds survival is comparable to that seen in younger patients in VIALE-A trial May 09, 2024
Impact of Recombinant Replacement Therapy Detailed in Genetic Clotting Disorder Trial that led to FDA approval shows a big difference in replacement levels versus usual care May 01, 2024
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management Genetics already informs prognosis, may help guide therapy development beyond JAK2 inhibition May 01, 2024
Myelofibrosis: A Rare Malignancy Attracting More and More Attention Increased interest follows mutation discoveries, development of targeted therapies May 01, 2024
New E. Coli Outbreak; How ECMO Redefines Death; A Step Closer to Universal Blood Health news and commentary gathered by Ƶ staff May 01, 2024
FDA Approves First Drug for WHIM Syndrome CXCR4 antagonist mavorixafor effectively boosts neutrophils and lymphocytes to reduce infections Apr 29, 2024
Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Records News, features, and commentary about cancer-related issues Apr 26, 2024
FDA OKs Second Gene Therapy for Hemophilia B One dose of fidanacogene elaparvovec proved noninferior to standard prophylactic factor IX Apr 26, 2024
Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT ORR reaches 90% with isatuximab plus KRd in newly diagnosed disease Apr 26, 2024
High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL Undetectable disease rate over 90%, ctDNA also promising for earlier detection of recurrence Apr 24, 2024
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers "All-in-one" approach appears safe, effective, in patients with relapsed/refractory disease Apr 24, 2024
Immunotherapy During Pregnancy Just as Safe as Other Cancer Drugs However, use should be avoided "if possible" due to risk of rare immune-related adverse events Apr 17, 2024
FDA Approves Earlier Use of CAR-T Products for Myeloma Carvykti and Abecma move to second- and third-line, respectively Apr 08, 2024
High Response Rate in R/R Multiple Myeloma With Bispecific Antibody ORR of 71% that deepened over time and favorable safety profile with linvoseltamab Apr 08, 2024
Factor D Inhibitor Wins Approval for PNH With Extravascular Hemolysis Danicopan significantly improved hemoglobin at 12 weeks when added to a C5 inhibitor Apr 04, 2024
